Compare SEAT & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEAT | XLO |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | 768 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6M | 49.8M |
| IPO Year | N/A | 2021 |
| Metric | SEAT | XLO |
|---|---|---|
| Price | $8.03 | $8.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | $18.06 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 109.0K | 32.1K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.60 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $1.42 | $0.46 |
| 52 Week High | $35.00 | $9.25 |
| Indicator | SEAT | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 53.90 |
| Support Level | $5.72 | $0.62 |
| Resistance Level | $10.27 | $9.03 |
| Average True Range (ATR) | 0.99 | 0.49 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 40.59 | 51.88 |
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.